1 Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center
4 A.Fib affects 2.2 million Americans. The lifetime risk for AF for men and women over age 40 is approximately 25% Increasing life expectancy is certain to lead to an increased prevalence of AF. Current estimates suggest that the prevalence of AF will reach 4 million by 2030 and climb to 5.6 million by 2050
5 Atrial fibrillation increases the risk of stroke approximately 5 fold Atrial fibrillation accounts for 36% of strokes in individuals years of age Strokes in individuals with atrial fibrillation are more disabling and more likely to recur than in individuals with stroke without atrial fibrillation
6 Stroke kills almost 130,000 Americans each year that s 1 out of every 19 deaths. On average, one American dies from stroke every 4 minutes. Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes. About 185,00 strokes (1/4) are in people who have had a previous stroke. About 87% of all strokes are ischemic strokes. Stroke costs the United States an estimated $36.5 billion each year. This total includes the cost of health care services, medications to treat stroke, and missed days of work. Stroke is a leading cause of serious long-term disability
25 Dabigatran etexilate (Pradaxa) is the first oral direct thrombin inhibitor to be approved by the US Food and Drug Administration (FDA).
26 Dabigatran etexilate is a prodrug that is rapidly converted to its active compound, dabigatran, by nonspecific esterases in the plasma and liver. This active compound competitively & reversibly binds to the active site of free and clot-bound thrombin, thereby blocking its procoagulant activity
27 An oral direct thrombin inhibitor approved for : 1. Stroke prevention in atrial fibrillation 2. Treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for 5-10 days 3. Long term prevention of recurrent DVT/PE in patients who have been previously treated for DVT/PE
41 FOR ATRIAL FIBRILLATION P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. P-gp inhibitors (e.g. dronedarone or systemic ketoconazole) increases the exposure to dabigatran. In patients with moderate renal impairment (CrCl ml/min), consider reducing the dose of PRADAXA to 75 mg twice daily when administered concomitantly with these agents. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, ticagrelor does not require a dose adjustment of PRADAXA. The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl ml/min) should be avoided. FOR DVT / PE - Avoid use of PRADAXA and P-gp inhibitors in patients with CrCl <50 ml/min
46 Rivaroxaban (Xarelto) is the second novel oral anticoagulant and the first oral direct coagulation factor Xa inhibitor approved for clinical use in the United States.
47 Rivaroxaban (Xarelto) reversibly binds to the active site of coagulation factor Xa without antithrombin mediation affecting free and platelet-bound factor Xa.
48 An oral direct factor Xa inhibitor approved for: 1. Stroke prevention in atrial fibrillation (20mg daily, or 15mg daily in patients with CrCl 15-50) 2. Treatment of DVT/PE (15mg bid for 21 days, then 20mg daily) 3. Prevention of DVT/PE following total hip or knee replacement (10mg daily)
49 Rivaroxaban is approved by the FDA, EMA, and HPFB for use in the primary prevention of VTE in adult patients who have undergone elective THA or TKA, the prevention of stroke and systemic embolism in patients with nonvalvular AF, the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE after initial treatment.
51 Large double-blind, double-dummy, noninferiority study versus dose-adjusted warfarin in 14,264 patients with nonvalvular atrial fibrillation (AF) Patients had multiple comorbidities with CHADS 2 scores 2 reflecting an increased risk of stroke. 87% had CHADS 2 score 3, reflecting an elevated risk for stroke. The primary efficacy outcome was the composite of stroke and non-cns systemic embolism.
58 The average duration of treatment during the extended trial was 190 days.
66 A oral direct factor Xa inhibitor approved for stroke and systemic embolism prevention in non-valvular atrial fibrillation, treatment of DVT/PE and prophylaxis of VTE post knee and hip surgery.
67 Apixaban (Eliquis) the third novel oral anticoagulant and second direct coagulation factor Xa inhibitor approved for clinical use in the United States.
68 Apixaban selectively and reversibly inhibits free and clot-bound factor Xa as well as prothrombinase activity.
79 Trial RE-LY ARISTOTLE ROCKET-AF Design Randomized Open Label N=18,113 Randomized Double blind N=18,209 Randomized double blind & dummy N=14,000 Treatment Dabigatran Apixaban Rivaroxaban 150 mg, BID 5 mg, BID 20 mg, Qday 110 mg, BID Comparator Warfarin 2-3 (67% TTR) Warfarin 2-3 (66% TTR) Warfarin 2-3 (57.8% TTR) Mean CHADS Time Therapeutic Range = TTR Modified Ahrens I, et al Thromb Haemost 2011;105
80 Study NOAC VKA Outcome RE-LY Dabigatran Warfarin RR % 1.7% 95% CI P < superiority ARISTOTLE Apixaban Warfarin HR % 1.6% 95% CI P= < Non- I P= 0.01 Superiority ROCKET-AF Rivaroxaban Warfarin HR % 2.2% 95% CI P = <0.001 Non-Inferiority
81 Study NOAC VKA Outcome RE-LY Dabigatran Warfarin RR % 3.6% 95% CI P = 0.31 ARISTOTLE Apixaban Warfarin HR % 3.1% 95% CI P = < ROCKET-AF Rivaroxaban Warfarin HR % 5.4% 95% CI P = 0.58
82 Study NOAC VKA Outcome RE-LY Dabigatran Warfarin RR % 0.7% 95% CI P= <0.001 ARISTOTLE Apixaban Warfarin HR % 0.8% 95% CI P = <0.001 ROCKET-AF Rivaroxaban Warfarin HR % 0.7% 95% CI P = 0.02
New Oral Anticoagulants: Thinning out the competition Ashlee D. Gerfen, Pharm.D. University of Arizona Medical Center PGY2 Critical Care Pharmacy Resident DISCLOSURE I have no financial interest, arrangement,
Update on Anticoagulants Jay Gaddy, MD, PhD Indiana Hemophilia & Thrombosis Center Indianapolis, Indiana None Disclosures Overview General discussion of anticoagulants New oral anticoagulants (NOACs) and
Novel Anticoagulants: Case of Mr. T Your Orthopedic surgeon calls you from the operating room requesting advice on VTE prevention for a 45yo male with congenital hip dysplasia and a remote history of DVT,
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
NOACs 2013: Evolving Anticoagulation Options Erik Yeo MD University Health Network University of Toronto Objectives Clinical overview the new oral anticoagulants and their management issues Rivaroxaban
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
Drug Class Review: Target Specific Oral Anticoagulants Dabigatran (Pradaxa), Rivaroxaban (Xarelto), and Apixaban (Eliquis) September 2013 VHA Pharmacy Benefits Management Services, Medical Advisory Panel
PCNA Anticoagulation: Old and New Janet Long, MSN, ACNP, CLS, FAHA, FNLA, FPCNA Objectives Identify the steps in the coagulation cascade in which warfarin, dabigatran, rivaroxaban and apixaban work Identify
New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis
Atrial Fibrillation Current State of Management with Importance to Newer Anticoagulants and Devices Garland Green, MD Interventional Cardiologist Cardiovascular Institute of the South Disclosures: Speaker
Anticoagulants Therapeutic Class Review (TCR) October 17, 2014 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,
Practical Use of Rivaroxaban in Atrial Fibrillation Dr Seow Swee-Chong KHRS, Seoul Jun 2012 MBBS, MRCP(UK), EHRA (Electrophysiology), EHRA (Cardiac Pacing), FAMS (Cardiology), FESC, FACC Director, Cardiac
Anticoagulants Therapeutic Class Review (TCR) February 16, 2014 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
Rivaroxaban Expanding Beyond Orthopedics Peter Thomson Clinical Resource Pharmacist, WRHA Medicine Program Clinical Asst Professor, Faculty of Pharmacy, University of Manitoba Objectives Compare key pharmacologic
Financial Disclosure Statement I have no relevant financial interests with respect to this subject. Teddie Gould, Pharm. D, BCPS Associate Professor of Pharmacy Practice College of Pharmacy, Idaho State
Practical Recommendations on Incorporating New Oral Anticoagulants Into Routine Practice Jaskirat Randhawa, MD, Nirosshan Thiruchelvam, MD, Michael Ghobrial, MD, Timothy Spiro, MD, Bernadette Clark, PharmD,
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
Newer oral anticoagulants This bulletin principally discusses the use of the three newer oral anticoagulants licensed for use in the UK dabigatran etexilate, apixaban, and rivaroxaban for the prevention
Cardiovascular Pharmacology Update Bo Bergeson PharmD., BCPS Disclosure I am not affiliated with nor do I have any financial ties to any pharmaceutical companies that manufacture the medications discussed
Rivaroxaban Practical Experience in the Cardiology Setting Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013 Overview of phase III clinical trials of new oral anticoagulants